In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diversified Pharmaceutical Services Inc.

Latest From Diversified Pharmaceutical Services Inc.

The Year in Deals: Hold That Acquisition!

After several years of intense consolidation, many medical products companies--the healthier ones, at least--seem to be taking a breather. Drug mergers are way down, while medical devices has become a buyer's market. And biotech consolidation isn't likely anytime soon. Only in slow-growing diagnostics is consolidation the rage.

BioPharmaceutical Medical Device

The Glaxo/SmithKline Debacle: Unanswered Questions

The proposed merger of SmithKline Beecham and Glaxo Wellcome PLC sent waves of anxiety when it was announced--and relief when it was canceled. The deal ran aground because of disagreements over who would run the company. But the larger questions it raised--about the need for greater critical mass in R&D and the likelihood of future mergers--won't go away so easily.

BioPharmaceutical Business Strategies

Express Scripts' Friendly Data Play

PBMs have historically positioned themselves as drug-industry antagonists, pushing generic substitution and aggressively driving prices lower. But now one independent PBM is arguing that far from being in the enemy camp, branded pharmaceuticals, even high cost ones, can actually contribute to reducing overall medical costs by lowering spending in other areas. And they're developing the data to prove it.

BioPharmaceutical Clinical Trials

Winning at the Risk Management Game

Customers are seeking risk based relationships with manufacturers, but developing such offerings requires a new way of thinking and a new set of capabilities. For companies that play the game well, risk can also offer rewards.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services